Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma
Standard
Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. / Schnapauff, Dirk; Denecke, Timm; Grieser, Christian; Collettini, Federico; Colletini, Federico; Seehofer, Daniel; Sinn, Marianne; Banzer, Jan; Lopez-Hänninen, Enrique; Hamm, Bernd; Wust, Peter; Gebauer, Bernhard.
in: CARDIOVASC INTER RAD, Jahrgang 35, Nr. 3, 06.2012, S. 581-7.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma
AU - Schnapauff, Dirk
AU - Denecke, Timm
AU - Grieser, Christian
AU - Collettini, Federico
AU - Colletini, Federico
AU - Seehofer, Daniel
AU - Sinn, Marianne
AU - Banzer, Jan
AU - Lopez-Hänninen, Enrique
AU - Hamm, Bernd
AU - Wust, Peter
AU - Gebauer, Bernhard
PY - 2012/6
Y1 - 2012/6
N2 - PURPOSE: This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation.METHOD: Fifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 (±90) ml (range, 10-257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan-Meier method.RESULTS: After a median follow-up of 18 (range, 1-27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months.CONCLUSION: In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.
AB - PURPOSE: This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation.METHOD: Fifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 (±90) ml (range, 10-257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan-Meier method.RESULTS: After a median follow-up of 18 (range, 1-27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months.CONCLUSION: In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.
KW - Aged
KW - Aged, 80 and over
KW - Bile Duct Neoplasms
KW - Bile Ducts, Intrahepatic
KW - Brachytherapy/methods
KW - Chi-Square Distribution
KW - Cholangiocarcinoma/diagnostic imaging
KW - Contrast Media
KW - Female
KW - Gadolinium DTPA
KW - Humans
KW - Kaplan-Meier Estimate
KW - Liver Neoplasms/diagnostic imaging
KW - Magnetic Resonance Imaging
KW - Male
KW - Middle Aged
KW - Radiography, Interventional/methods
KW - Retrospective Studies
KW - Tomography, X-Ray Computed/methods
KW - Treatment Outcome
U2 - 10.1007/s00270-011-0249-0
DO - 10.1007/s00270-011-0249-0
M3 - SCORING: Journal article
C2 - 21833806
VL - 35
SP - 581
EP - 587
JO - CARDIOVASC INTER RAD
JF - CARDIOVASC INTER RAD
SN - 0174-1551
IS - 3
ER -